Entry - #619764 - CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1H; CMT1H - OMIM
 
# 619764

CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1H; CMT1H


Alternative titles; symbols

HEREDITARY MOTOR AND SENSORY NEUROPATHY, IH
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1H
NEUROPATHY, HEREDITARY, WITH OR WITHOUT AGE-RELATED MACULAR DEGENERATION; HNARMD


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
14q32.12 Charcot-Marie-Tooth disease, demyelinating, type 1H 619764 AD 3 FBLN5 604580
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal dominant
HEAD & NECK
Eyes
- Age-related macular degeneration (rare)
SKELETAL
- Joint hypermobility (rare)
Feet
- Foot deformities
SKIN, NAILS, & HAIR
Skin
- Hyperelastic skin (rare)
MUSCLE, SOFT TISSUES
- Distal muscle weakness due to peripheral neuropathy, lower limbs more affected than upper limbs
- Distal muscle atrophy due to peripheral neuropathy, lower limbs more affected than upper limbs
NEUROLOGIC
Peripheral Nervous System
- Peripheral neuropathy, demyelinating (upper and lower limb involvement)
- Distal sensory impairment
- Unpleasant sensation in the upper limbs
- Impaired gait
- Decreased deep tendon reflexes
- Decreased nerve conduction velocities
- Loss of myelinated fibers seen on sural nerve biopsy
- Onion bulb formations
- Poorly myelinated axons
- Axonal features (in some patients)
MISCELLANEOUS
- Adult onset (median age 39 years)
- Both upper and lower limbs are involved
- Slowly progressive
MOLECULAR BASIS
- Caused by mutation in the fibulin 5 gene (FBLN5, 604580.0012)
Charcot-Marie-Tooth disease - PS118220 - 82 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.31 Charcot-Marie-Tooth disease, recessive intermediate C AR 3 615376 PLEKHG5 611101
1p36.22 Charcot-Marie-Tooth disease, type 2A1 AD 3 118210 KIF1B 605995
1p36.22 Hereditary motor and sensory neuropathy VIA AD 3 601152 MFN2 608507
1p36.22 Charcot-Marie-Tooth disease, axonal, type 2A2B AR 3 617087 MFN2 608507
1p36.22 Charcot-Marie-Tooth disease, axonal, type 2A2A AD 3 609260 MFN2 608507
1p35.1 Charcot-Marie-Tooth disease, dominant intermediate C AD 3 608323 YARS1 603623
1p13.1 Charcot-Marie-Tooth disease, axonal, type 2DD AD 3 618036 ATP1A1 182310
1q22 Charcot-Marie-Tooth disease, type 2B1 AR 3 605588 LMNA 150330
1q23.2 Charcot-Marie-Tooth disease, axonal, type 2FF AD 3 619519 CADM3 609743
1q23.3 Charcot-Marie-Tooth disease, type 2J AD 3 607736 MPZ 159440
1q23.3 Dejerine-Sottas disease AD, AR 3 145900 MPZ 159440
1q23.3 Charcot-Marie-Tooth disease, type 1B AD 3 118200 MPZ 159440
1q23.3 Charcot-Marie-Tooth disease, type 2I AD 3 607677 MPZ 159440
1q23.3 Charcot-Marie-Tooth disease, dominant intermediate D AD 3 607791 MPZ 159440
2p23.3 Charcot-Marie-Tooth disease, axonal, type 2EE AR 3 618400 MPV17 137960
3q21.3 Charcot-Marie-Tooth disease, type 2B AD 3 600882 RAB7 602298
3q25.2 Charcot-Marie-Tooth disease, axonal, type 2T AD, AR 3 617017 MME 120520
3q26.33 Charcot-Marie-Tooth disease, dominant intermediate F AD 3 615185 GNB4 610863
4q31.3 Charcot-Marie-Tooth disease, type 2R AR 3 615490 TRIM2 614141
5q31.3 Charcot-Marie-Tooth disease, axonal, type 2W AD 3 616625 HARS1 142810
5q32 Charcot-Marie-Tooth disease, type 4C AR 3 601596 SH3TC2 608206
6p21.31 Charcot-Marie-Tooth disease, demyelinating, type 1J AD 3 620111 ITPR3 147267
6q21 Charcot-Marie-Tooth disease, type 4J AR 3 611228 FIG4 609390
7p14.3 Charcot-Marie-Tooth disease, type 2D AD 3 601472 GARS1 600287
7q11.23 Charcot-Marie-Tooth disease, axonal, type 2F AD 3 606595 HSPB1 602195
8p21.2 Charcot-Marie-Tooth disease, type 2E AD 3 607684 NEFL 162280
8p21.2 Charcot-Marie-Tooth disease, type 1F AD, AR 3 607734 NEFL 162280
8p21.2 Charcot-Marie-Tooth disease, dominant intermediate G AD 3 617882 NEFL 162280
8q13-q23 Charcot-Marie-Tooth disease, axonal, type 2H AR 2 607731 CMT2H 607731
8q21.11 {?Charcot-Marie-Tooth disease, axonal, autosomal dominant, type 2K, modifier of} AD, AR 3 607831 JPH1 605266
8q21.11 Charcot-Marie-Tooth disease, axonal, type 2K AD, AR 3 607831 GDAP1 606598
8q21.11 Charcot-Marie-Tooth disease, type 4A AR 3 214400 GDAP1 606598
8q21.11 Charcot-Marie-Tooth disease, recessive intermediate, A AR 3 608340 GDAP1 606598
8q21.11 Charcot-Marie-Tooth disease, axonal, with vocal cord paresis AR 3 607706 GDAP1 606598
8q21.13 Charcot-Marie-Tooth disease, demyelinating, type 1G AD 3 618279 PMP2 170715
8q24.22 Charcot-Marie-Tooth disease, type 4D AR 3 601455 NDRG1 605262
9p13.3 Charcot-Marie-Tooth disease, type 2Y AD 3 616687 VCP 601023
9q33.3-q34.11 Charcot-Marie-Tooth disease, axonal, type 2P AD, AR 3 614436 LRSAM1 610933
9q34.2 Charcot-Marie-Tooth disease, type 4K AR 3 616684 SURF1 185620
10p14 ?Charcot-Marie-Tooth disease, axonal, type 2Q AD 3 615025 DHTKD1 614984
10q21.3 Hypomyelinating neuropathy, congenital, 1 AD, AR 3 605253 EGR2 129010
10q21.3 Charcot-Marie-Tooth disease, type 1D AD 3 607678 EGR2 129010
10q21.3 Dejerine-Sottas disease AD, AR 3 145900 EGR2 129010
10q22.1 Neuropathy, hereditary motor and sensory, Russe type AR 3 605285 HK1 142600
10q24.32 Charcot-Marie-Tooth disease, axonal, type 2GG AD 3 606483 GBF1 603698
10q26.11 Charcot-Marie-Tooth disease, axonal, type 2JJ AD 3 621095 BAG3 603883
11p15.4 Charcot-Marie-Tooth disease, type 4B2 AR 3 604563 SBF2 607697
11q13.3 Charcot-Marie-Tooth disease, axonal, type 2S AR 3 616155 IGHMBP2 600502
11q21 Charcot-Marie-Tooth disease, type 4B1 AR 3 601382 MTMR2 603557
12p11.21 Charcot-Marie-Tooth disease, type 4H AR 3 609311 FGD4 611104
12q13.3 Charcot-Marie-Tooth disease, axonal, type 2U AD 3 616280 MARS1 156560
12q23.3 Charcot-Marie-Tooth disease, demyelinating, type 1I AD 3 619742 POLR3B 614366
12q24.11 Hereditary motor and sensory neuropathy, type IIc AD 3 606071 TRPV4 605427
12q24.23 Charcot-Marie-Tooth disease, axonal, type 2L AD 3 608673 HSPB8 608014
12q24.31 Charcot-Marie-Tooth disease, recessive intermediate D AR 3 616039 COX6A1 602072
14q32.12 Charcot-Marie-Tooth disease, demyelinating, type 1H AD 3 619764 FBLN5 604580
14q32.31 Charcot-Marie-Tooth disease, axonal, type 2O AD 3 614228 DYNC1H1 600112
14q32.33 Charcot-Marie-Tooth disease, dominant intermediate E AD 3 614455 INF2 610982
15q14 Charcot-Marie-Tooth disease, axonal, type 2II AD 3 620068 SLC12A6 604878
15q21.1 Charcot-Marie-Tooth disease, axonal, type 2X AR 3 616668 SPG11 610844
16p13.13 Charcot-Marie-Tooth disease, type 1C AD 3 601098 LITAF 603795
16q22.1 Charcot-Marie-Tooth disease, axonal, type 2N AD 3 613287 AARS1 601065
16q23.1 ?Charcot-Marie-Tooth disease, recessive intermediate, B AR 3 613641 KARS1 601421
17p12 Charcot-Marie-Tooth disease, type 1A AD 3 118220 PMP22 601097
17p12 Dejerine-Sottas disease AD, AR 3 145900 PMP22 601097
17p12 Charcot-Marie-Tooth disease, type 1E AD 3 118300 PMP22 601097
17q21.2 ?Charcot-Marie-Tooth disease, axonal, type 2V AD 3 616491 NAGLU 609701
19p13.2 Charcot-Marie-Tooth disease, dominant intermediate B AD 3 606482 DNM2 602378
19p13.2 Charcot-Marie-Tooth disease, axonal type 2M AD 3 606482 DNM2 602378
19q13.2 Dejerine-Sottas disease AD, AR 3 145900 PRX 605725
19q13.2 Charcot-Marie-Tooth disease, type 4F AR 3 614895 PRX 605725
19q13.33 ?Charcot-Marie-Tooth disease, type 2B2 AR 3 605589 PNKP 605610
20p12.2 Charcot-Marie-Tooth disease, axonal, type 2HH AD 3 619574 JAG1 601920
22q12.2 Charcot-Marie-Tooth disease, axonal, type 2CC AD 3 616924 NEFH 162230
22q12.2 Charcot-Marie-Tooth disease, axonal, type 2Z AD 3 616688 MORC2 616661
22q13.33 Charcot-Marie-Tooth disease, type 4B3 AR 3 615284 SBF1 603560
Xp22.2 Charcot-Marie-Tooth neuropathy, X-linked recessive, 2 XLR 2 302801 CMTX2 302801
Xp22.11 ?Charcot-Marie-Tooth disease, X-linked dominant, 6 XLD 3 300905 PDK3 300906
Xq13.1 Charcot-Marie-Tooth neuropathy, X-linked dominant, 1 XLD 3 302800 GJB1 304040
Xq22.3 Charcot-Marie-Tooth disease, X-linked recessive, 5 XLR 3 311070 PRPS1 311850
Xq26 Charcot-Marie-Tooth neuropathy, X-linked recessive, 3 XLR 4 302802 CMTX3 302802
Xq26.1 Cowchock syndrome XLR 3 310490 AIFM1 300169

TEXT

A number sign (#) is used with this entry because of evidence that demyelinating Charcot-Marie-Tooth disease-1H (CMT1H) is caused by heterozygous mutation in the gene encoding fibulin-5 (FBLN5; 604580) on chromosome 14q32.

Heterozygous mutation in the FBLN5 gene can also cause autosomal dominant cutis laxa-2 (ADCL2; 614434) and isolated age-related macular degeneration-3 (ARMD3; 608895). Skin laxity and ARMD may rarely occur in patients with CMT1H.


Description

Demyelinating Charcot-Marie-Tooth disease-1H (CMT1H) is an autosomal dominant peripheral sensorimotor neuropathy with onset usually in adulthood (third to fifth decades). Affected individuals present with foot deformities, upper or lower limb sensory disturbances, and motor deficits, mainly impaired gait. Of note, many patients complain of unpleasant sensory sensations in the upper extremities and hands. The disorder is slowly progressive and becomes more apparent with age, although patients usually remain ambulatory. Other features include hypo- or areflexia, limb muscle weakness, and impaired gait. Electrophysiologic studies are consistent with a demyelinating polyneuropathy. Rare patients may have hyperelastic skin or develop age-related macular degeneration (summary by Auer-Grumbach et al., 2011 and Safka Brozkova et al., 2020)

For a discussion of genetic heterogeneity of autosomal dominant Charcot-Marie-Tooth disease type 1, see CMT1B (118200).


Clinical Features

Auer-Grumbach et al. (2011) reported a large Austrian kindred (families A and B) in which multiple individuals spanning several generations had demyelinating CMT. Eight patients were studied in detail. The severity of the phenotype was variable, but common features included distal muscle weakness and atrophy variably affecting the lower and upper limbs and distal sensory impairment. The age at onset ranged from 25 to 50 years. Most patients had hypo- or areflexia, and several had symptoms consistent with carpal tunnel syndrome. None had hyperelastic skin, and only the oldest patient had age-related macular degeneration at age 81 years. Electrophysiologic studies performed in some patients showed decreased nerve conduction velocities, consistent with a demyelinating peripheral neuropathy.

Another family (family C) with 5 members reported by Auer-Grumbach et al. (2011) had more variable manifestation of a peripheral neuropathy. Two brothers had early onset of spinal CMT at age 4. They had severe distal muscle weakness and wasting predominantly of the lower limbs without sensory impairment. In addition, they both had hyperelastic skin, joint hypermobility, high palate, and mild skeletal abnormalities; neither had macular degeneration at 19 and 21 years of age. Nerve conduction velocities suggested an axonal neuropathy, and EMG showed chronic neurogenic disturbances, but sural nerve biopsy was normal. Family studies identified a parent, grand-aunt, and grandparent who had mild peripheral neuropathy and hyporeflexia. The parent also had hyperelastic skin, whereas the grand-aunt had ARMD at age 71 years. In a third family (family D), a 46-year-old proband had spinal CMT with onset at age 20 and hyperelastic skin. The father was asymptomatic but had evidence of a mild peripheral neuropathy of the lower limbs; he also had ARMD at age 82 years. Six additional patients with sporadic occurrence of ARMD who were over the age of 79 years were subsequently found to have variable features of peripheral neuropathy, and 2 patients in their eighties had sporadic peripheral neuropathy without ARMD. Auer-Grumbach et al. (2011) concluded that the overall phenotype in these patients represented a novel syndrome associated with FBLN5 gene mutations, including presence of peripheral neuropathy with or without ARMD and occasionally hyperelastic skin, with intrafamilial variability.

Safka Brozkova et al. (2013) reported a large family of Czech descent with CMT1H. Affected individuals had onset in their twenties of distal muscle atrophy and weakness affecting mainly the lower limbs, with some patients having weakness of the upper limbs. Two older patients reported distal sensory impairment. Some younger patients were clinically asymptomatic, but electrophysiologic studies indicated a demyelinating peripheral neuropathy. Patellar reflexes were decreased or absent in all patients. None had hyperelastic skin or ARMD.

Cheng et al. (2017) reported a Chinese family with CMT1H. The 46-year-old proband developed distal numbness and muscle weakness at age 34 years when he was also diagnosed with diabetes mellitus. The neurologic disorder was slowly progressive, and he developed gait difficulties and distal sensory impairment of several modalities in both the lower and upper limbs. Other features included hypo- or areflexia, steppage gait, and atrophy of the distal muscles of the upper and lower limbs. The disorder remained essentially static over about 10 years. The patient's 81-year-old mother had a mild peripheral neuropathy with distal sensory impairment, areflexia, and pes cavus; she developed age-related macular degeneration and cataract of the right eye. The proband's 16-year-old daughter had no clinical symptoms, although deep tendon reflexes were absent. Electrophysiologic studies in all 3 patients were indicative of a demyelinating sensorimotor neuropathy with more prominent findings in the proband, who was the most severely affected. Ultrasound detected abnormally enlarged nerves, and sural nerve biopsy of the proband showed a decrease in myelinated fibers as well as the presence of onion bulb formations and poorly myelinated axons.

Safka Brozkova et al. (2020) reported 38 affected individuals from 19 families with CMT1H confirmed by genetic analysis. The families were of Austrian, Czech, French, and German origin; 3 of the families had previously been reported. Most patients were diagnosed between the third and fifth decades (median 39 years of age), and the presenting features included foot deformities, upper or lower limb sensory disturbances, and motor deficits, mainly impaired gait. Of note, many patients complained of unpleasant sensory sensations in the upper extremities and hands. In retrospect, many patients had foot deformities since childhood, but had no physical limitations at that time. The disorder was slowly progressive and became more apparent with age, although all remained ambulatory and had purposeful hand use. Several younger individuals carrying the mutation were clinically asymptomatic, although decreased reflexes and foot deformities were noted. None had hyperelastic skin; 1 patient had age-related macular degeneration at age 81. Electrophysiologic studies were consistent with a demyelinating polyneuropathy.


Inheritance

The transmission pattern of CMT1H in the families reported by Auer-Grumbach et al. (2011) and Safka Brozkova et al. (2013) was consistent with autosomal dominant inheritance with variable expressivity and age-dependent penetrance.


Molecular Genetics

In affected members of 3 families with CMT1H, Auer-Grumbach et al. (2011) identified 3 different heterozygous missense mutations in the FBLN5 gene (604580.0012-604580.0014). Functional studies of the variants were not performed.

Safka Brozkova et al. (2013) identified a heterozygous missense mutation in the FBLN5 gene (R373C; 604580.0012) in affected members of a Czech family with CMT1H. The mutation, which was found by exome sequencing and confirmed by Sanger sequencing, segregated with the disorder in the family.

In 3 affected members spanning 3 generations of a Chinese family with CMT1H, Cheng et al. (2017) identified a heterozygous R373C mutation in the FBLN5 gene (604580.0012).

In affected members of 19 families with CMT1H, some of whom had previously been reported, Safka Brozkova et al. (2020) identified 3 different heterozygous missense mutations in the FBLN5 gene. R373C (604580.0012) was the most common mutation, occurring in 15 families of Austrian, Czech, and French origin. Three families of Czech or German origin carried a heterozygous R331H mutation (604580.0015), and 1 French family carried a D329V mutation (604580.0016). The mutations, which were detected by Sanger sequencing, multigene panel sequencing, or whole-exome sequencing, segregated with the disorder in families from whom DNA was available for the affected members. Functional studies of the variants were not performed, but they were either absent from or found only once in the gnomAD database.


REFERENCES

  1. Auer-Grumbach, M., Weger, M., Fink-Puches, R., Papic, L., Frohlich, E., Auer-Grumbach, P., El Shabrawi-Caelen, L., Schabhuttl, M., Windpassinger, E., Senderek, J., Budka, H., Trajanoski, S., Janecke, A. R., Haas, A., Metze, D., Pieber, T. R., Guelly, C. Fibulin-5 mutations link inherited neuropathies, age-related macular degeneration and hyperelastic skin. Brain 134: 1839-1852, 2011. [PubMed: 21576112, images, related citations] [Full Text]

  2. Cheng, S., Lv, H., Zhang, W., Wang, Z., Shi, X., Liang, W., Yuan, Y. Adult-onset demyelinating neuropathy associated with FBLN5 gene mutation. Clin. Neuropath. 36: 171-177, 2017. [PubMed: 28332470, images, related citations] [Full Text]

  3. Safka Brozkova, D., Lassuthova, P., Neupauerova, J., Krutova, M., Haberlova, J., Stejskal, D., Seeman, P. Czech family confirms the link between FBLN5 and Charcot-Marie-Tooth type 1 neuropathy. (Letter) Brain 136: e232, 2013. Note: Electronic Article. [PubMed: 23328402, related citations] [Full Text]

  4. Safka Brozkova, D., Stojkovic, T., Haberlova, J., Mazanec, R., Windhager, R., Fernandes Rosenegger, P., Hacker, S., Zuchner, S., Kochanski, A., Leonard-Louis, S., Francou, B., Latour, P., Senderek, J., Seeman, P., Auer-Grumbach, M. Demyelinating Charcot-Marie-Tooth neuropathy associated with FBLN5 mutations. Europ. J. Neurol. 27: 2568-2574, 2020. [PubMed: 32757322, related citations] [Full Text]


Creation Date:
Cassandra L. Kniffin : 02/23/2022
alopez : 03/02/2022
alopez : 03/02/2022
ckniffin : 02/24/2022

# 619764

CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1H; CMT1H


Alternative titles; symbols

HEREDITARY MOTOR AND SENSORY NEUROPATHY, IH
CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1H
NEUROPATHY, HEREDITARY, WITH OR WITHOUT AGE-RELATED MACULAR DEGENERATION; HNARMD


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
14q32.12 Charcot-Marie-Tooth disease, demyelinating, type 1H 619764 Autosomal dominant 3 FBLN5 604580

TEXT

A number sign (#) is used with this entry because of evidence that demyelinating Charcot-Marie-Tooth disease-1H (CMT1H) is caused by heterozygous mutation in the gene encoding fibulin-5 (FBLN5; 604580) on chromosome 14q32.

Heterozygous mutation in the FBLN5 gene can also cause autosomal dominant cutis laxa-2 (ADCL2; 614434) and isolated age-related macular degeneration-3 (ARMD3; 608895). Skin laxity and ARMD may rarely occur in patients with CMT1H.


Description

Demyelinating Charcot-Marie-Tooth disease-1H (CMT1H) is an autosomal dominant peripheral sensorimotor neuropathy with onset usually in adulthood (third to fifth decades). Affected individuals present with foot deformities, upper or lower limb sensory disturbances, and motor deficits, mainly impaired gait. Of note, many patients complain of unpleasant sensory sensations in the upper extremities and hands. The disorder is slowly progressive and becomes more apparent with age, although patients usually remain ambulatory. Other features include hypo- or areflexia, limb muscle weakness, and impaired gait. Electrophysiologic studies are consistent with a demyelinating polyneuropathy. Rare patients may have hyperelastic skin or develop age-related macular degeneration (summary by Auer-Grumbach et al., 2011 and Safka Brozkova et al., 2020)

For a discussion of genetic heterogeneity of autosomal dominant Charcot-Marie-Tooth disease type 1, see CMT1B (118200).


Clinical Features

Auer-Grumbach et al. (2011) reported a large Austrian kindred (families A and B) in which multiple individuals spanning several generations had demyelinating CMT. Eight patients were studied in detail. The severity of the phenotype was variable, but common features included distal muscle weakness and atrophy variably affecting the lower and upper limbs and distal sensory impairment. The age at onset ranged from 25 to 50 years. Most patients had hypo- or areflexia, and several had symptoms consistent with carpal tunnel syndrome. None had hyperelastic skin, and only the oldest patient had age-related macular degeneration at age 81 years. Electrophysiologic studies performed in some patients showed decreased nerve conduction velocities, consistent with a demyelinating peripheral neuropathy.

Another family (family C) with 5 members reported by Auer-Grumbach et al. (2011) had more variable manifestation of a peripheral neuropathy. Two brothers had early onset of spinal CMT at age 4. They had severe distal muscle weakness and wasting predominantly of the lower limbs without sensory impairment. In addition, they both had hyperelastic skin, joint hypermobility, high palate, and mild skeletal abnormalities; neither had macular degeneration at 19 and 21 years of age. Nerve conduction velocities suggested an axonal neuropathy, and EMG showed chronic neurogenic disturbances, but sural nerve biopsy was normal. Family studies identified a parent, grand-aunt, and grandparent who had mild peripheral neuropathy and hyporeflexia. The parent also had hyperelastic skin, whereas the grand-aunt had ARMD at age 71 years. In a third family (family D), a 46-year-old proband had spinal CMT with onset at age 20 and hyperelastic skin. The father was asymptomatic but had evidence of a mild peripheral neuropathy of the lower limbs; he also had ARMD at age 82 years. Six additional patients with sporadic occurrence of ARMD who were over the age of 79 years were subsequently found to have variable features of peripheral neuropathy, and 2 patients in their eighties had sporadic peripheral neuropathy without ARMD. Auer-Grumbach et al. (2011) concluded that the overall phenotype in these patients represented a novel syndrome associated with FBLN5 gene mutations, including presence of peripheral neuropathy with or without ARMD and occasionally hyperelastic skin, with intrafamilial variability.

Safka Brozkova et al. (2013) reported a large family of Czech descent with CMT1H. Affected individuals had onset in their twenties of distal muscle atrophy and weakness affecting mainly the lower limbs, with some patients having weakness of the upper limbs. Two older patients reported distal sensory impairment. Some younger patients were clinically asymptomatic, but electrophysiologic studies indicated a demyelinating peripheral neuropathy. Patellar reflexes were decreased or absent in all patients. None had hyperelastic skin or ARMD.

Cheng et al. (2017) reported a Chinese family with CMT1H. The 46-year-old proband developed distal numbness and muscle weakness at age 34 years when he was also diagnosed with diabetes mellitus. The neurologic disorder was slowly progressive, and he developed gait difficulties and distal sensory impairment of several modalities in both the lower and upper limbs. Other features included hypo- or areflexia, steppage gait, and atrophy of the distal muscles of the upper and lower limbs. The disorder remained essentially static over about 10 years. The patient's 81-year-old mother had a mild peripheral neuropathy with distal sensory impairment, areflexia, and pes cavus; she developed age-related macular degeneration and cataract of the right eye. The proband's 16-year-old daughter had no clinical symptoms, although deep tendon reflexes were absent. Electrophysiologic studies in all 3 patients were indicative of a demyelinating sensorimotor neuropathy with more prominent findings in the proband, who was the most severely affected. Ultrasound detected abnormally enlarged nerves, and sural nerve biopsy of the proband showed a decrease in myelinated fibers as well as the presence of onion bulb formations and poorly myelinated axons.

Safka Brozkova et al. (2020) reported 38 affected individuals from 19 families with CMT1H confirmed by genetic analysis. The families were of Austrian, Czech, French, and German origin; 3 of the families had previously been reported. Most patients were diagnosed between the third and fifth decades (median 39 years of age), and the presenting features included foot deformities, upper or lower limb sensory disturbances, and motor deficits, mainly impaired gait. Of note, many patients complained of unpleasant sensory sensations in the upper extremities and hands. In retrospect, many patients had foot deformities since childhood, but had no physical limitations at that time. The disorder was slowly progressive and became more apparent with age, although all remained ambulatory and had purposeful hand use. Several younger individuals carrying the mutation were clinically asymptomatic, although decreased reflexes and foot deformities were noted. None had hyperelastic skin; 1 patient had age-related macular degeneration at age 81. Electrophysiologic studies were consistent with a demyelinating polyneuropathy.


Inheritance

The transmission pattern of CMT1H in the families reported by Auer-Grumbach et al. (2011) and Safka Brozkova et al. (2013) was consistent with autosomal dominant inheritance with variable expressivity and age-dependent penetrance.


Molecular Genetics

In affected members of 3 families with CMT1H, Auer-Grumbach et al. (2011) identified 3 different heterozygous missense mutations in the FBLN5 gene (604580.0012-604580.0014). Functional studies of the variants were not performed.

Safka Brozkova et al. (2013) identified a heterozygous missense mutation in the FBLN5 gene (R373C; 604580.0012) in affected members of a Czech family with CMT1H. The mutation, which was found by exome sequencing and confirmed by Sanger sequencing, segregated with the disorder in the family.

In 3 affected members spanning 3 generations of a Chinese family with CMT1H, Cheng et al. (2017) identified a heterozygous R373C mutation in the FBLN5 gene (604580.0012).

In affected members of 19 families with CMT1H, some of whom had previously been reported, Safka Brozkova et al. (2020) identified 3 different heterozygous missense mutations in the FBLN5 gene. R373C (604580.0012) was the most common mutation, occurring in 15 families of Austrian, Czech, and French origin. Three families of Czech or German origin carried a heterozygous R331H mutation (604580.0015), and 1 French family carried a D329V mutation (604580.0016). The mutations, which were detected by Sanger sequencing, multigene panel sequencing, or whole-exome sequencing, segregated with the disorder in families from whom DNA was available for the affected members. Functional studies of the variants were not performed, but they were either absent from or found only once in the gnomAD database.


REFERENCES

  1. Auer-Grumbach, M., Weger, M., Fink-Puches, R., Papic, L., Frohlich, E., Auer-Grumbach, P., El Shabrawi-Caelen, L., Schabhuttl, M., Windpassinger, E., Senderek, J., Budka, H., Trajanoski, S., Janecke, A. R., Haas, A., Metze, D., Pieber, T. R., Guelly, C. Fibulin-5 mutations link inherited neuropathies, age-related macular degeneration and hyperelastic skin. Brain 134: 1839-1852, 2011. [PubMed: 21576112] [Full Text: https://doi.org/10.1093/brain/awr076]

  2. Cheng, S., Lv, H., Zhang, W., Wang, Z., Shi, X., Liang, W., Yuan, Y. Adult-onset demyelinating neuropathy associated with FBLN5 gene mutation. Clin. Neuropath. 36: 171-177, 2017. [PubMed: 28332470] [Full Text: https://doi.org/10.5414/NP301011]

  3. Safka Brozkova, D., Lassuthova, P., Neupauerova, J., Krutova, M., Haberlova, J., Stejskal, D., Seeman, P. Czech family confirms the link between FBLN5 and Charcot-Marie-Tooth type 1 neuropathy. (Letter) Brain 136: e232, 2013. Note: Electronic Article. [PubMed: 23328402] [Full Text: https://doi.org/10.1093/brain/aws333]

  4. Safka Brozkova, D., Stojkovic, T., Haberlova, J., Mazanec, R., Windhager, R., Fernandes Rosenegger, P., Hacker, S., Zuchner, S., Kochanski, A., Leonard-Louis, S., Francou, B., Latour, P., Senderek, J., Seeman, P., Auer-Grumbach, M. Demyelinating Charcot-Marie-Tooth neuropathy associated with FBLN5 mutations. Europ. J. Neurol. 27: 2568-2574, 2020. [PubMed: 32757322] [Full Text: https://doi.org/10.1111/ene.14463]


Creation Date:
Cassandra L. Kniffin : 02/23/2022

Edit History:
alopez : 03/02/2022
alopez : 03/02/2022
ckniffin : 02/24/2022